George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca Growth Regulatory News (HYG)

Share Price Information for Seneca Growth (HYG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.50
Bid: 10.00
Ask: 17.00
Change: 0.00 (0.00%)
Spread: 7.00 (70.00%)
Open: 13.50
High: 13.50
Low: 13.50
Prev. Close: 13.50
HYG Live PriceLast checked at -
Seneca Growth Capital VCT is an Investment Trust

To provide shareholders with an attractive income and capital return by investing its funds in a portfolio of both unquoted and quoted UK MedTech companies which meet the relevant criteria under the VCT Rules.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Changes

18 May 2023 13:38

Directorate Changes

Directorate Changes

Seneca Growth Capital VCT Plc (the "Company")

18 May 2023

Appointment of Non-Executive Director and Appointment of Chair of the Audit Committee

Non-Executive Director

The Board of Seneca Growth Capital VCT Plc is delighted to announce that Mary Anne Cordeiro was today appointed to the Board as non-executive Director of the Company. Mary Anne has also joined the Company’s Audit Committee.

Mary Anne brings to the Board extensive knowledge of both the VCT and growth capital investment sectors, having been an advisor to or executive of innovative companies in the healthcare and technology sectors for over twenty years. Mary Anne has served as a non-executive Director of Albion Technology & General VCT Plc (“AATG”) from 2013 until 2023, following its merger with Albion Income & Growth VCT Plc where she had served as a non-executive Director from 2004. Having served nine years as non-executive Director, more recently as Senior Independent Director and Chair of the Remuneration Committee, Mary Anne is retiring from the AATG Board today. Mary Anne is also the Founder and Managing Director of Science to Business Limited which specialises in advising medical technology businesses on fundraising and commercialisation strategy. Prior to this Mary Anne had a fifteen-year career in international corporate finance as a M&A Investment Banker at Goldman Sachs International Limited, Vice President at Bankers Trust Company and Managing Director of Paribas’ Financial Institutions Group. Mary Anne holds a MA (Hons) in Chemistry from the University of Oxford and is a member of the University of Oxford’s Department of Chemistry Development Board.

Mary Anne will stand for election at the Annual General Meeting of the Company to be held in 2024. There is no additional information required to be disclosed pursuant to Listing Rule 9.6.13 in relation to the appointment of Mary Anne.

Chair of the Audit Committee

We are also pleased to announce that further to Richard Roth’s retirement from the Board , with effect from today’s Annual General Meeting, Alex Clarkson has been appointed as Chair of the Audit Committee. Alex qualified as a Chartered Accountant with PwC in 1998 and has served as an independent non-executive Director of the Company and been a member of the Audit Committee since 2019.

These appointments are in accordance with the Board’s succession plans as outlined in the Company’s 2022 Annual Report, which was published on 21 April 2023.

Board Composition

The Board maintains its composition of four non-executive Directors, comprising three independent non-executive Directors and one representative of the Company’s Investment Manager, Seneca Partners Limited.

The Company’s Board is mindful of the new Listing Rule requirements which came into force for accounting periods starting after 1 April 2022 which require the Company to either comply with, or explain its non-compliance with, new rules intended to improve the diversity of publicly listed Boards.

The new rules seek to achieve 40% Board representation from women, one senior board position to be held by a woman and one Director to be from an ethnic minority background. Whilst the Company does not yet fully comply with the requirements, the Board will continue to work to improve the Board’s composition, providing suitable candidates possess the key skills and experience required for the position. The Board will always appoint the best person for the job. It will not discriminate on the grounds of gender, race, ethnicity, religion, sexual orientation, age or physical ability. The Board also fully supports the aims of the Hampton Alexander Report, the Parker Review and the renewed focus and emphasis on diversity in the AIC Code of Corporate Governance.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Date   Source Headline
22nd Apr 202410:46 amGNWShare Buy-back and Total Voting Rights
5th Apr 202412:44 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20247:00 amGNWNet Asset Value(s)
28th Mar 202412:11 pmGNWIssue of Supplementary Prospectus
22nd Mar 20247:00 amGNWFinal Results, Notice of AGM, Updated NAV
7th Mar 20247:00 amGNWInterim Dividend on B Shares
19th Feb 20244:36 pmGNWDirector Declaration
21st Dec 202312:03 pmGNWIssue of Equity and Total Voting Rights
6th Dec 20233:24 pmGNWDirector/PDMR Dealing
6th Dec 20233:14 pmGNWIssue of Equity and Total Voting Rights
29th Nov 202312:36 pmGNWChange of the Company’s Auditor
20th Nov 20233:20 pmGNWB Share Buy-back and Total Voting Rights
3rd Nov 20237:00 amGNWDividend Declaration
12th Oct 20237:00 amGNWNet Asset Value(s)
11th Oct 20233:39 pmGNWDirectorate Change
24th Aug 20234:18 pmGNWOffer for Subscription and Publication of Prospectus
18th Aug 20235:08 pmGNWIssue of Equity and Total Voting Rights and Capital Reorganisation
2nd Aug 202311:40 amGNWHalf-year Report
30th Jun 20231:58 pmGNWIssue of Equity and Total Voting Rights
20th Jun 20238:50 amGNWShare Buy-back and Total Voting Rights
18th May 20231:38 pmGNWDirectorate Changes
18th May 20231:32 pmGNWResults of Annual General Meeting Voting
3rd May 20234:01 pmGNWIssue of Equity and Total Voting Rights
27th Apr 202311:25 amGNWPublication of a Supplementary Prospectus
21st Apr 20237:00 amGNWFinal Results for the Year Ended 31 December 2022
5th Apr 20233:05 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20237:00 amGNWNet Asset Value(s)
7th Mar 20231:30 pmGNWInterim Dividend Declarations
21st Dec 20227:00 amGNWB Share Portfolio Update
7th Dec 20227:00 amGNWOrdinary Share NAV Update and Dividend Declaration
30th Nov 202212:33 pmGNWDirector/PDMR Shareholding
30th Nov 202212:29 pmGNWIssue of Equity and Total Voting Rights
19th Oct 20227:00 amGNWSecond Interim Dividend on B Shares
13th Oct 20227:00 amGNWNAV Update
26th Aug 202211:56 amGNWOffer for Subscription and Publication of Prospectus
22nd Aug 20222:53 pmGNWPDMR Shareholding
22nd Aug 20222:46 pmGNWIssue of Equity and Total Voting Rights
16th Aug 20227:00 amGNWB Share Closure of Offer for Subscription
15th Jul 20227:00 amGNWHalf-year report
30th Jun 202210:17 amGNWIssue of Supplementary Prospectus
23rd May 20227:00 amGNWAppointment of Auditor
23rd May 20227:00 amGNWShare Buy-back and TVR
4th May 202211:25 amGNWIssue of Equity and Total Voting Rights
27th Apr 20223:42 pmGNWResult of AGM
5th Apr 20221:56 pmGNWIssue of Equity and Total Voting Rights
1st Apr 20221:43 pmGNWIssue of Equity and Total Voting Rights
1st Apr 202211:05 amGNWNAV Update
25th Mar 202210:00 amGNWIssue of Supplementary Prospectus
25th Mar 20227:01 amGNWNAV Update
25th Mar 20227:00 amGNWFinal Results for the Year Ended 31 December 2021

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.